PE20220562A1 - Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida - Google Patents

Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida

Info

Publication number
PE20220562A1
PE20220562A1 PE2022000116A PE2022000116A PE20220562A1 PE 20220562 A1 PE20220562 A1 PE 20220562A1 PE 2022000116 A PE2022000116 A PE 2022000116A PE 2022000116 A PE2022000116 A PE 2022000116A PE 20220562 A1 PE20220562 A1 PE 20220562A1
Authority
PE
Peru
Prior art keywords
methyl
methoxyazetidin
dihydropyridin
methylthio
carboxamide
Prior art date
Application number
PE2022000116A
Other languages
English (en)
Inventor
Victor S Gehling
Alamelu Banda
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of PE20220562A1 publication Critical patent/PE20220562A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripcion se refiere a una Forma cristalina 1 de 7-cloro-2-(4-(3-metoxiazetidin-1- il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3- il)metil)benzo[d][1,3]dioxol-5-carboxamida, que es util como modulador de la actividad de las enzimas modificadoras de metilo de las histonas. Estas formas cristalinas se emplean en el tratamiento de enfermedades o trastornos que responden a la inhibicion de EZH2, por ejemplo, el cancer.
PE2022000116A 2019-07-24 2020-07-23 Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida PE20220562A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962878012P 2019-07-24 2019-07-24
PCT/US2020/043178 WO2021016414A1 (en) 2019-07-24 2020-07-23 Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide

Publications (1)

Publication Number Publication Date
PE20220562A1 true PE20220562A1 (es) 2022-04-13

Family

ID=72047059

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000116A PE20220562A1 (es) 2019-07-24 2020-07-23 Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida

Country Status (14)

Country Link
US (1) US20220251073A1 (es)
EP (2) EP4003532B1 (es)
JP (1) JP2022541630A (es)
KR (1) KR20220041129A (es)
CN (1) CN114450279B (es)
AU (1) AU2020316073A1 (es)
BR (1) BR112022001161A2 (es)
CA (1) CA3148447A1 (es)
CL (1) CL2022000175A1 (es)
CO (1) CO2022001482A2 (es)
IL (1) IL289972A (es)
MX (1) MX2022000931A (es)
PE (1) PE20220562A1 (es)
WO (1) WO2021016414A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN118541367A (zh) * 2022-01-14 2024-08-23 同和药品株式会社 1,3-苯并间二氧杂环戊烯衍生物化合物及包含该化合物的药物组合物
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2024015566A1 (en) 2022-07-15 2024-01-18 Constellation Pharmaceuticals, Inc. Ezh2 inhibition therapies for the treatment of at-rich interactive domain-containing protein 1a (arid1a) mutated cancers
CN115403040B (zh) * 2022-08-11 2023-08-01 中国地质大学（北京） 一种可通过光辐射调控导热系数的偶氮苯聚合物表面修饰的金刚石纳米粒子及其制备方法
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators
WO2024076663A1 (en) 2022-10-06 2024-04-11 Constellation Pharmaceuticals, Inc. Ezh2 inhibition therapies for the treatment of brca1-associated protein (bap1) mutated cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606135TA (en) * 2012-01-25 2016-09-29 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
KR102219441B1 (ko) * 2013-02-11 2021-02-23 콘스텔레이션 파마슈티칼스, 인크. 메틸 변형 효소 조절제, 이의 조성물 및 용도
KR102302830B1 (ko) * 2014-03-17 2021-09-15 다이이찌 산쿄 가부시키가이샤 1,3-벤조디옥솔 유도체
US10577350B2 (en) * 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
US11311524B2 (en) * 2017-01-19 2022-04-26 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
AR114793A1 (es) * 2018-04-18 2020-10-14 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos

Also Published As

Publication number Publication date
BR112022001161A2 (pt) 2022-06-07
EP4003532B1 (en) 2024-09-04
CO2022001482A2 (es) 2022-03-18
CN114450279B (zh) 2024-07-09
CA3148447A1 (en) 2021-01-28
US20220251073A1 (en) 2022-08-11
CN114450279A (zh) 2022-05-06
WO2021016414A1 (en) 2021-01-28
EP4003532A1 (en) 2022-06-01
JP2022541630A (ja) 2022-09-26
CL2022000175A1 (es) 2022-09-20
MX2022000931A (es) 2022-05-03
AU2020316073A1 (en) 2022-02-17
KR20220041129A (ko) 2022-03-31
IL289972A (en) 2022-03-01
EP4442261A2 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
PE20220562A1 (es) Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
CL2019003586A1 (es) Composiciones y métodos para enzimas de internalización.
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
EA201990202A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
UY35596A (es) Compuestos para la modulación de quinasas, y sus indicaciones
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
CL2018001996A1 (es) Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16)
EA201790740A1 (ru) Индолкарбоксамидные соединения
BR112015026380A2 (pt) esteróides 19-nor-c3,3-c21-n-pirazolil dissubstituídos e métodos de utilização dos mesmos
CO2021008018A2 (es) Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
GT201300258A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
BR112022011917A2 (pt) Fluoroalquil-oxadiazois e seus usos
CL2016002827A1 (es) Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
BR112018076486A2 (pt) formas sólidas cristalinas de um inibidor de bet
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
CA2904533C (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
BR112015022907A8 (pt) formas cristalinas de sal de (2-(2-(4-fluorfenil) tiazol-4-il) propan-2-il) carbamato de (s)-quinuclidin-3-ila e seus usos
BR112017025263A2 (pt) método para o tratamento de doença neurológica
AR115081A1 (es) Aislados de microbacterias y sus usos
BR112015016206A2 (pt) moduladores de ship1 e métodos relacionados com os mesmos
MX2022004373A (es) Celulas madre modificadas y metodos de uso de las mismas.